P53- and mevalonate pathway–driven malignancies require Arf6 for metastasis and drug resistanceAri Hashimoto, Hisataka Sabe|The Journal of Cell Biology|2016Cited by 58
ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistanceAri Hashimoto, Hisataka Sabe|Oncogenesis|2016Cited by 45